Although systemic androgen deprivation therapy remains the standard therapy for metastatic castrate-sensitive prostate cancer, regardless of lesion count, emerging clinical data support the integration of PSMA-PET/CT with MDT in this patient group. This evidence concerns the gene FOLH1 and prostate carcinoma.